Changes in sleep-wake patterns are among the hallmarks of biological aging. Previously, we reported that impaired melatonin secretion is associated with sleep disorders old age. In this study investigated effects replacement therapy on melatonin-dencient elderly insomniacs. The comprised a running-in, no-treatment period and four experimental periods. During second, third fourth periods, subjects were administered tablets for 7 consecutive days, 2 hours before desired bedtime. either mg as...

<h3>Background and aims</h3> The aim of this project was to introduce an innovative leadership programme aimed at hospice nurses within the community palliative care team help enhance their skills build resilience reduce risk burnout. develop nursing skills, patient improve practitioner self-management. To ensure reflects needs individuals group as a whole, range teaching learning methods were employed. included Myers Briggs Type Indicator (MBTI), FIERCE training, training on self-management...

Summary Melatonin, secreted nocturnally by the pineal gland, is an endogenous sleep regulator. Impaired melatonin production and complaints on poor quality of are common among elderly. Non‐restorative (perceived sleep) subsequently daytime functioning increasingly recognized as a leading syndrome in diagnostic therapeutic process insomnia complaints. The effects 3‐weeks prolonged‐release 2 mg (PR‐melatonin) versus placebo treatment were assessed multi‐center randomized placebo‐controlled...

Melatonin, the hormone produced nocturnally by pineal gland, serves as a circadian time cue and sleep-anticipating signal in humans. With age, melatonin production declines prevalence of sleep disorders, particularly insomnia, increases. The efficacy safety prolonged release formulation (PR-melatonin; Circadin* 2 mg) were examined insomnia patients aged 55 years older.Randomised, double blind, placebo-controlled.Primary care.From 1248 pre-screened 523 attending visit 1, 354 males females...

Melatonin is extensively used in the USA a non-regulated manner for sleep disorders. Prolonged release melatonin (PRM) licensed Europe and other countries short term treatment of primary insomnia patients aged 55 years over. However, clear definition target patient population well-controlled studies long-term efficacy safety are lacking. It known that production declines with age. Some young also may have low levels. The study investigated whether older age or excretion better predictor...

Abstract: The major protein in isolated synaptic vesicles from bovine cerebral cortex has been compared to tubulin by sodium dodecyl sulphate‐urea polyacrylamide gel electrophoresis, two‐dimensional electrophoresis and peptide mapping following limited proteolysis of the Staphylococcus aureus protease. results establish purified presence tubulin, which is composed α β subunits. In ethyleneglycol bis (aminoethyl ether)‐ N, N' ‐tetraacetic acid (EGTA) or magnesium isolation buffers, contained...

A link between poor sleep quality and Alzheimer's disease (AD) has recently been suggested. Since endogenous melatonin levels are already reduced at preclinical AD stages, it is important to ask whether replenishing the missing hormone would be beneficial in any such effects related presence of disorder patients.The add-on prolonged-release (PRM) (2 mg) standard therapy on cognitive functioning were investigated 80 patients (men [50.7%], women [49.3%], average age 75.3 years [range, 52-85...

Objective: A recent double-blind randomized placebo-controlled study demonstrated 3-month efficacy and safety of a novel pediatric-appropriate prolonged-release melatonin (PedPRM) for insomnia in children adolescents with autism spectrum disorder (ASD) neurogenetic disorders (NGD) with/without attention-deficit/hyperactivity comorbidity. Long-term PedPRM treatment was studied. Methods: prospective, open-label follow-up nightly 2, 5, or 10 mg subjects who completed the 13-week trial (51...

Background: Diabetes is a major comorbidity in insomnia patients. The efficacy and safety of prolonged-release melatonin 2 mg the treatment glucose, lipid metabolism, sleep was studied 36 type diabetic patients with (11 men, 25 women, age 46–77 years). Methods: In randomized, double-blind, crossover study, subjects were treated for 3 weeks (period 1) or placebo, followed by one-week washout period, then crossed over another 2) other preparation. All tablets taken hours before bedtime period...

ObjectiveA recent 3-month double-blind, placebo-controlled study demonstrated efficacy and safety of pediatric prolonged-release melatonin (PedPRM) for insomnia in children with autism spectrum disorder. This examined the long-term effects PedPRM treatment on sleep, growth, body mass index, pubertal development.MethodEighty adolescents (2–17.5 years age; 96% disorder) who completed trial were given 2 mg, 5 or 10 mg nightly up to 104 weeks, followed by a 2-week placebo period assess...

A randomized, 13-weeks, placebo-controlled double-blind study in 125 subjects aged 2–17.5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy safety of easily-swallowed prolonged-release melatonin mini-tablets (PedPRM; 2–5 mg) improving sleep duration onset. Treatment effects on child behavior caregiver's quality life were evaluated. PedPRM treatment resulted significant improvement externalizing but not internalizing (Strengths Difficulties...

Article AbstractBackground: Accumulating evidence indicates decreased melatonin levels in patients with schizophrenia. Insomnia, mainly difficulty falling asleep at night, is commonly reported this population. Association of insomniawith low or abnormal rhythms has been repeatedly documented. Melatonin an endogenous sleep promoter humans. We hypothesized that insomnia schizophrenia may be partially due to diminished output. In study, we measured output chronic and assessed the effects...

Abstract Background Melatonin is an important regulator of the sleep–wake cycle. A prolonged‐release formulation melatonin (PR‐M) that essentially mimics profile endogenous production hormone effective in treatment insomnia patients aged 55 years and older. Because hypnotics result impairments various cognitive skills, it to examine effects associated with use PR‐M. Objectives methods The therapeutic oral doses PR‐M (2 mg), zolpidem (10 mg) their combination administered at bedtime on...